0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Evidence to Practice |

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value

Jeffrey A. Tice, MD1; Dhruv S. Kazi, MD, MSc, MS2,3,4; Steven D. Pearson, MD, MSc5
[+] Author Affiliations
1Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
2Division of Cardiology, Department of Medicine, University of California San Francisco
3Department of Epidemiology and Biostatistics, University of California, San Francisco
4Center for Healthcare Value, University of California, San Francisco
5Institute for Clinical and Economic Review, Boston, Massachusetts
JAMA Intern Med. 2016;176(1):107-108. doi:10.1001/jamainternmed.2015.7248.
Text Size: A A A
Published online

Extract

This evidence summary reviews the comparative clinical effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitor for the treatment of adults with familial hypercholesterolemia or cardiovascular disease and who require additional lowering of low-density lipoprotein cholesterol levels.

Article InformationCorresponding Author: Jeffrey A. Tice, MD, Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero St, Box 0320, San Francisco, CA 94143-0320 (jtice@medicine.ucsf.edu).

Published Online: December 14, 2015. doi:10.1001/jamainternmed.2015.7248.

Conflict of Interest Disclosures: None reported.

Additional Information: The New England Comparative Effectiveness Public Advisory Council is a program of the Institute for Clinical and Economic Review and is supported by grants from the New England States Consortium Systems Organization and the Laura and John Arnold Foundation.

Additional Contributions: We acknowledge the contributions of the following individuals to the development of this article: Kirsten Bibbins-Domingo, MD, PhD, MAS, Pamela G. Coxson, PhD, Joanne Penko, MS, MPH, and David Guzman, MSPH, of the University of California San Francisco; Andrew E. Moran, MD, of Columbia University; and Daniel A. Ollendorf, PhD, Courtney Cunningham, MPH, Erin Lawler, Matt Seider, and Richard Chapman, PhD, of the Institute for Clinical and Economic Review.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Cost-effectiveness Analysis of PCSK9 Inhibitor Treatment in 4 Cost Scenarios

The lines represent results from 4 scenarios, varying possible annual drug prices, percentage of eligible patients treated, and their effect on cost-effectiveness ratios and the potential effect on budget. PCSK9 indicates proprotein convertase subtilisin/kexin type 9; QALY, quality-adjusted life-year.

Graphic Jump Location

Tables

References

Correspondence

CME


You need to register in order to view this quiz.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

3,389 Views
6 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
What are the Results?

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
How Much Does Allowing for Uncertainty Change the Results?

brightcove.createExperiences();